Arch Therapeutics Announces Appointment of Guy Fish to the Board
04 janv. 2022 09h47 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
13 déc. 2021 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program
01 déc. 2021 07h50 HE
|
Arch Therapeutics, Inc.
Renowned Expert Dr. Christopher Gauland Shares Insights on Treating DFUs and Success with AC5® Advanced Wound System FRAMINGHAM, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc....
Arch Therapeutics Launches Experts in Wound Care Program
18 oct. 2021 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Launches Coverage and Reimbursement Pilot
04 oct. 2021 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer
03 mai 2021 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today...
Arch Therapeutics, Inc. to Present at the Virtual Investor Fireside Chat Series
08 juin 2020 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, today announced that...
UPDATE - Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
07 oct. 2019 15h59 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
07 oct. 2019 11h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat
05 août 2019 07h50 HE
|
Arch Therapeutics, Inc.
Studies highlight antimicrobial activity for AC5 technology platform; AC5™ Topical Hemostat1 under Review by Notified Body FRAMINGHAM, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics,...